Previous reports showed that AR is expressed in approximately 60.5% of breast cancer (4658/7693) and is involved in multiple signaling pathways to modulate cellular processes; thus, it is a promising drug target in clinical applications [83,84]. Here, AR is linked to breast carcinoma.